Literature DB >> 8817805

Failed stereotactic biopsy in a series of 518 cases.

T M Soo1, M Bernstein, J Provias, R Tasker, A Lozano, A Guha.   

Abstract

Failed stereotactic biopsy is one in which a definitive histological or microbiological diagnosis is not achieved based on the tissue obtained. Of 518 consecutive CT-guided stereotactic biopsies of intra-axial mass lesions, 42 (8.1%) cases were failed biopsies. Inflammatory changes were seen in 10 cases (24%); gliosis was seen in 11 cases (26%); 9 cases (21%) yielded necrotic specimens; normal brain was retrieved in 7 cases (17%); blood/hemorrhagic brain was seen in 3 cases and in 2 cases, no tissue could be obtained. Variables that significantly influenced the diagnostic success included the immune status (HIV positive; p < 0.001). The complication rate in the failed biopsy group was significantly higher. The subsequent management and outcome of patients who suffered a failed stereotactic biopsy are discussed.

Entities:  

Mesh:

Year:  1995        PMID: 8817805     DOI: 10.1159/000098747

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  14 in total

1.  In vivo characterization of several rodent glioma models by 1H MRS.

Authors:  Sabrina Doblas; Ting He; Debra Saunders; Jessica Hoyle; Nataliya Smith; Quentin Pye; Megan Lerner; Randy L Jensen; Rheal A Towner
Journal:  NMR Biomed       Date:  2011-09-23       Impact factor: 4.044

Review 2.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors.

Authors:  A Lin; S Bluml; A N Mamelak
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

4.  Frame-based stereotactic biopsy remains an important diagnostic tool with distinct advantages over frameless stereotactic biopsy.

Authors:  Justin S Smith; Alfredo Quiñones-Hinojosa; Nicholas M Barbaro; Michael W McDermott
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

5.  Factors affecting diagnostic yield in stereotactic biopsy for brain lesions: a 5-year single-center series.

Authors:  Bik Liang Lau; Kugan Vijian; Donald Ngian San Liew; Albert Sii Hieng Wong
Journal:  Neurosurg Rev       Date:  2021-10-10       Impact factor: 3.042

Review 6.  Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment.

Authors:  James Rubenstein; Andrés J M Ferreri; Stefania Pittaluga
Journal:  Leuk Lymphoma       Date:  2008

7.  Prognostic Value of Conventional Magnetic Resonance Imaging for Adult Patients with Brain Tumors.

Authors:  L Klingelhöfer; D Mucha; K Geiger; R Koch; R von Kummer
Journal:  Clin Neuroradiol       Date:  2014-05-15       Impact factor: 3.649

8.  Diffusion tensor magnetic resonance imaging of rat glioma models: a correlation study of MR imaging and histology.

Authors:  Silun Wang; Jinyuan Zhou
Journal:  J Comput Assist Tomogr       Date:  2012 Nov-Dec       Impact factor: 1.826

9.  A Liquid Biopsy to Assess Brain Tumor Recurrence: Presence of Circulating Mo-MDSC and CD14+ VNN2+ Myeloid Cells as Biomarkers That Distinguish Brain Metastasis From Radiation Necrosis Following Stereotactic Radiosurgery.

Authors:  David C Soler; Amber Kerstetter-Fogle; Theresa Elder; Alankrita Raghavan; Jill S Barnholtz-Sloan; Kevin D Cooper; Thomas S McCormick; Andrew E Sloan
Journal:  Neurosurgery       Date:  2020-12-15       Impact factor: 4.654

10.  Diagnostic yield and morbidity by neuronavigation-guided frameless stereotactic biopsy using magnetic resonance imaging and by frame-based computed tomography-guided stereotactic biopsy.

Authors:  Masamitsu Nishihara; Naoya Takeda; Tomoaki Harada; Keiji Kidoguchi; Shoutarou Tatsumi; Kazuhiro Tanaka; Takashi Sasayama; Eiji Kohmura
Journal:  Surg Neurol Int       Date:  2014-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.